Bright Minds Biosciences Inc.
DRUG · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.99 | 0.00 | -10.94 | 0.01 |
| FCF Yield | -1.39% | -1.05% | -0.65% | -6.56% |
| EV / EBITDA | -61.07 | -52.88 | -108.21 | -1.89 |
| Quality | ||||
| ROIC | -6.34% | -6.00% | 0.00% | -13.52% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.67 | 0.82 | -30.12 | 0.60 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -44.48% | -62.29% | -222.64% | -292.86% |
| Safety | ||||
| Net Debt / EBITDA | 15.62 | 16.67 | 36.00 | 7.25 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |